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Abstract
Background: To evaluate the efficacy of triple therapy consisting of single-session photodynamic therapy
(PDT), intravitreal bevacizumab (IVB) and intravitreal triamcinolone (IVT) as initial pulse therapy followed
by repeat intravitreal bevacizumab injections for maintenance treatment in neovascular age-related
macular degeneration (AMD).
Methods: In a prospective interventional case series, patients with subfoveal choroidal neovascularization
(CNV) secondary to AMD underwent pulse therapy with single-session PDT according to the standard
protocol followed by 1.25 mg IVB and 2 mg IVT 48 hours later. Best corrected visual acuity (BCVA) was
assessed and optical coherence tomography (OCT) and fluorescein angiography (FA) were performed
prior to treatment. BCVA and OCT measurements were repeated at 6 week intervals and FA was
obtained after 12 weeks and when necessary thereafter. Repeat injections of IVB were performed based
on fluorescein angiographic evidence of CNV leakage.
Results: This series included 17 eyes of 17 patients with mean age of 67.6 ± 7.2 years. Mean follow up
duration was 50.4 ± 15.5 weeks. Mean BCVA prior to treatment was 0.74 ± 0.33 logMAR which improved
to 0.52 ± 0.36 logMAR after 12 weeks (P = 0.012) and 0.41 ± 0.38 logMAR after 24 weeks (P = 0.001).
Mean pretreatment central macular thickness (CMT) was 395 ± 181µ which was significantly reduced to
217 ± 69µ (P = 0.005), 231 ± 79µ (P = 0.028) and 221 ± 87µ (P = 0.05) six, twelve and twenty-four weeks
after initial treatment respectively. Visual acuity improvement and CMT reduction was maintained during
the follow-up period. IVB injections were repeated once, twice and three times in 10, 7 and 2 eyes at a
mean interval of 20.2 ± 10.1, 19 ± 13.7 and 15 ± 1.4 weeks after initial therapy, respectively.
Conclusion: Initial pulse triple therapy consisting of single-session PDT combined with IVB and IVT
improves vision and reduces CMT in neovascular AMD. Repeat IVB injections maintain the visual gain from
the initial combination therapy.
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Background
Photodynamic therapy is an FDA-approved treatment for
neovascular age-related macular degeneration (AMD);
however this treatment modality seems to stabilize, rather
than improve vision [1-3]. Furthermore, need for numer-
ous retreatments with possible adverse effects on physio-
logical choroid [4-7] and concerns about cost are
important drawbacks of monotherapy with PDT. Triamci-
nolone is an angiostatic steroid with inhibitory effect on
choroidal microvascular endothelial cell migration and
tube formation [8]. Intravitreal triamcinolone mono-
therapy has been used for treatment of neovascular AMD
with modest short-term effects; the long-term results of
these studies however have been disappointing [9-11].
Potential complications of intravitreal triamcinolone
include glaucoma and cataract formation or progression.
The risk of these complications increase with repeat injec-
tions [11,12]. Recent studies have shown that combining
intravitreal triamcinolone with PDT is superior to mono-
therapy in terms of visual improvement and reduced need
for retreatments [13-18]. Bevacizumab is a full-length
humanized anti-VEGF antibody which has recently
gained popularity for treatment of neovascular AMD.
Intravitreal injection of bevacizumab may improve visual
acuity, decrease retinal thickness and reduce angiographic
leakage in AMD [19]. Monotherapy with bevacizumab
however, necessitates multiple intravitreal injections
within 4–6 week intervals and each injection carries the
risk of serious complications. It has been suggested that
antiangiogenic drugs may also be combined with PDT as
an effective treatment modality [20-22].
Combination of PDT with intravitreal injection of an anti-
angiogenesis drug and a steroid may address the multifac-
torial pathogenesis of AMD, improve vision and reduce
the need for retreatments. Results of triple therapy with
PDT, bevacizumab and dexamethasone have been
reported recently [23]. We performed a pilot study to eval-
uate the efficacy of pulse triple therapy with single-session
photodynamic therapy, intravitreal bevacizumab and
intravitreal triamcinolone in all types of neovascular
AMD. Repeat intravitreal injections of bevacizumab were
given as maintenance therapy. Herein, we report the
results of this therapeutic approach.
Methods
The study was a prospective, interventional case series.
The treatment protocol was approved by the Ethics Com-
mittee of the Ophthalmic Research Center. Patients were
informed about the risks and benefits of combined ther-
apy and written consent was obtained. Eyes with all types
of active subfoveal CNV secondary to neovascular AMD
with lesions less than 4 disc areas and Snellen visual acu-
ity of 20/30 to 20/400 at baseline were included. Exclu-
sion criteria were glaucoma, diabetic retinopathy, macular
disorders other than AMD and previous treatment for
CNV.
Eligible eyes were evaluated before treatment completely.
Best corrected visual acuity measured by Snellen chart was
recorded in logMAR. Applanation tonometry, anterior
segment examination with slit lamp and fundus examina-
tion was performed. All eyes underwent color fundus pho-
tography and fluorescein angiography (FA) using a
confocal scanning laser angiograph (Heidelberg Retina
Angiograph II: Heidelberg engineering). Optical coher-
ence tomography (Zeiss, Dublin, CA) was performed
before intervention for all cases to measure the central
macular thickness (CMT). Photodynamic therapy with
verteporfin was performed according to the standard regi-
men. Forty eight hours after PDT, intravitreal injection of
1.25 mg/0.05 ml bevacizumab (Avastin, made for F. Hoff-
mann- La Roche Ltd Basel, Switzerland by Genentech,
Inc., San Francisco, CA) and 2 mg/0.05 ml triamcinolone
acetonide(Triamhexal, Hexal AG, Holzkirchen, Germany)
was carried out at two different sites under sterile condi-
tion. A topical antibiotic, every 6 hours for 3 days, was
prescribed and patients were instructed to return in case of
ocular pain or redness or any deterioration of vision.
Patients were examined one day and one week after injec-
tion. Topical antiglaucoma medication was prescribed if
intraocular pressure (IOP) was more than 21 mmHg.
Visual acuity and optical coherence tomography (OCT)
were evaluated at 6 week intervals. Fluorescein angiogra-
phy was repeated at week 12 and when considered neces-
sary thereafter. CNV activity was defined as presence of
leakage from the CNV on fluorescein angiography. Eyes
with active CNV underwent repeat intravitreal injection of
1.25 mg bevacizumab. Repeat PDT and intravitreal triam-
cinolone injections were not considered in the study pro-
tocol.
Paired T-test was used to compare findings before and
after treatment.
Results
Seventeen eyes of 17 patients (7 male and 10 female) with
the mean age of 67.6 ± 7.2 years were included in this
study. Lesion types were predominantly classic in 5 eyes,
minimally classic in 3 eyes, occult in 8 eyes and retinal
angiomatous proliferation (RAP) in one eye. Mean fol-
low-up was 50.4 ± 15.5 weeks and all 17 patients com-
pleted the 24 week follow up (Table 1).
Mean BCVA was 0.74 ± 0.33 logMAR (range: 1.20 to 0.22)
before treatment (Table 1). BCVA improved to 0.52 ± 0.36
at week 12 following treatment (P = 0.012). Further
improvement to 0.36 ± 0.30 logMAR (P = 0.001) and 0.41
± 0.38 logMAR (P = 0.001) was observed at weeks 18 andBMC Ophthalmology 2007, 7:10 http://www.biomedcentral.com/1471-2415/7/10
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24 respectively (Figure 1). BCVA improved in 11 eyes
(64.7%) and remained unchanged in 6 eyes (35.3%) 12
weeks after the initial therapy. Corresponding figures were
13 eyes (76.5%) and 4 eyes (23.5%) respectively 24 weeks
after intervention (Table 1). Mean central macular thick-
ness (CMT) was 395 ± 181µ prior to treatment. Mean
CMT was reduced to 217 ± 69µ at week 6 (P = 0.005), 231
± 79µ at week 12 (P = 0.028) and 221 ± 87µ at week 24 (P
= 0.05). CMT reduction persisted during the follow-up
period (Figure 2).
Seven eyes (41.2%) remained stable following the initial
therapy. Follow up period for these 7 eyes ranged from 24
to 73 weeks (mean: 42.6 ± 17.6 weeks). A second intravit-
real injection of bevacizumab was required in 10 eyes
(58.8%), a third injection was performed in 7 eyes
(41.2%) and a fourth injection was needed in 2 eyes
(11.8%). Mean interval between the first and second
injections and between the second and third injections
were 20.2 ± 10.12 and 19 ± 13.7 weeks respectively. The
interval between the third and fourth injections had a
range of 14 to 16 weeks. Mean follow up for eyes with 2,
3 and 4 injections were 56 ± 11.6 weeks, 60.1 ± 5.5 weeks
and 58.5 ± 9.2 weeks respectively. No adverse ocular or
systemic events were observed during the follow up
period.
Mean IOP was 14 ± 1.9 mmHg before treatment and
increased to 17.3 ± 6.3 mmHg at week 6 and returned to
pretreatment levels 12 weeks after intervention. In one
patient IOP was increased to 34 mmHg after one week.
Intraocular pressure was controlled in this patient with a
combination of timolol eye drop bid and dorzolamide
eye drop every 8 hours, which were continued for 5 weeks.
Discussion
In this small case series, combination of single-session
PDT with intravitreal bevacizumab and triamcinolone
was used as pulse therapy for neovascular AMD. Our goal
was to increase the efficacy of treatment and reduce side
effects of monotherapy. Triple therapy resulted in signifi-
cant visual improvement and CMT reduction irrespective
of lesion type and also reduced the need for retreatments.
Visual acuity improved significantly in the majority of
cases in our series and remained unchanged in others.
This treatment effect persisted during the follow up
period. More than one third of our patients remained sta-
ble after the initial pulse therapy. The visual gain could be
maintained in the remaining cases with few retreatments.
Intravitreal bevacizumab was used for maintenance ther-
apy to avoid the side effects of repeat PDT and repeat
intravitreal triamcinolone. The average interval between
the first and second treatment sessions was about 20
weeks which may reflect less need for retreatment follow-
ing the initial pulse therapy.
Augustin et al recently published the results of triple ther-
apy with PDT, bevacizumab and dexamethasone for neo-
vascular AMD [23]. They concluded that triple therapy
results in significant visual improvement after one cycle of
treatment in most cases. Of 104 patients, 18 received an
additional intravitreal injection of bevacizumab at a mean
of 15 weeks after triple therapy. The authors employed a
second cycle of triple therapy in 5 cases due to recurrent,
Table 1: Patient characteristics and data for each patient
Patient no, Sex, Age (yrs) CNV Type Pretreatment BCVA 
(LogMAR)
24- week BCVA 
(LogMAR)
No of 
Retreatments
Follow-up (weeks)
1, M, 75 Occult 0.60 0.60 2 61
2, F, 64 Occult 0.90 0.90 0 73
3, M, 65 Minimally classic 0.78 0.48 0 46
4, F, 54 Occult 0.48 0.00 0 24
5, M, 65 Occult 1.20 0.10 2 68
6, F, 55 Classic 0.78 0.48 2 58
7, M, 67 Classic 0.30 0.00 1 56
8, F, 60 Classic 0.78 0.00 2 59
9, F, 68 RAP 0.60 0.10 2 57
10, M, 70 Occult 0.30 0.10 3 65
11, F, 75 Occult 0.60 0.40 0 52
12, F, 74 Classic 1.20 0.40 0 25
13, M, 73 Classic 0.48 0.30 3 52
14, F, 82 Minimally classic 1.20 1.20 1 57
15, F, 67 Minimally classic 0.22 0.15 1 26
16, F, 65 Occult 1.00 1.00 0 48
17, M, 71 Occult 1.10 0.78 0 30
Mean BCVA (Snellen) ± SD 0.74 (20/100) ± 0.33 0.41 (20/50) ± 0.38BMC Ophthalmology 2007, 7:10 http://www.biomedcentral.com/1471-2415/7/10
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angiographically detectable CNV activity. Avoiding repeat
PDT has been one of the principles of our strategy which
makes it different from the method described by Augustin
et al. We limited PDT to one session in our treatment pro-
tocol for two purposes: 1- To reduce the potential side
effects of PDT on the physiological choroidal vasculature,
RPE and neurosensory retina; 2- To reduce the cost of
treatment.
The rationale for single-session PDT emanates from the
present knowledge regarding the possible adverse effects
of repeat PDT on physiological choroid and even RPE and
neurosensory retina [24,25]. In a study by Schmidt-
Erfurth et al, the effects of multiple- PDT regimen were
evaluated [5]. Persistent hypofluorescence was docu-
mented in all patients after the second and third PDT.
Quantitative analysis showed 25% enlargement in the
hypofluorescent area one week after the second session of
PDT compared to the first [5]. In addition, multiple ses-
sions of PDT may accelerate the risk of CNV recurrence
due to aggravation of choroidal ischemia and subsequent
over-expression of VEGF [5]. Augustin et al tried to reduce
the potential side effects of PDT by reducing the light dose
[23]. This approach is however based on a hypothesis
which needs to be documented with further studies.
PDT may cause phototoxicity-induced VEGF expression
and increase vascular permeability by triggering genera-
tion of free radicals and lipid peroxides [26]. Triamci-
nolone has been shown to suppress the early
proangiogenic response in RPE cells after PDT in vitro
[27]. In addition to reversing some PDT-induced adverse
effects, triamcinolone may independently affect CNV [8].
There is no consensus on the optimal dose of IVT which is
particularly related to concerns about adverse effects. Sig-
nificant IOP elevation (ie, IOP>21 mmHg or requiring
medical or surgical therapy) has been reported in 21% to
43% of eyes undergoing either 4 mg or 25 mg IVT injec-
tion [9-11]. Repeat injections of IVT are associated with
more severe IOP rise [11,18]. We limited intravitreal tri-
amcinolone to one injection and used a lower dose to
reduce the adverse effects. By using the 2 mg dose of IVT,
the total volume of intravitreal injections was reduced to
0.1 cc (0.05 cc IVT and 0.05 cc IVB). There was no signifi-
cant difference between mean IOP before and after IVT
injections in our series. Significant IOP elevation was
observed only in one patient which was controlled with
topical medications.
We used intravitreal bevacizumab as one of the compo-
nents of pulse triple therapy. It was also used as a mainte-
nance therapy in our series. Use of an antiangiogenic
factor can counteract the PDT induced over-expression of
VEGF and reduce its adverse effects. On the other hand,
PDT may disrupt the architecture of CNV and help the
antiangiogenic factor to affect the lesion more potently
[21]. Aggio et al treated two cases of neovascular AMD
with a combination of PDT and intravitreal bevacizumab.
This resulted in anatomic success; however it was not
equally effective in terms of VA improvement due to pres-
ence of advanced disease in both patients [20]. Dhalla et
al reported the 7-month results of combined photody-
namic therapy and IVB for CNV secondary to AMD [21].
Visual acuity stabilization was observed in 83% and
improvement was noticed in 67%. Retreatment was
needed in 37% of their cases. Costa et al performed intra-
vitreal injection of bevacizumab one week after PDT [22].
The change in BCVA from baseline was significant at 12
Significant reduction of CMT was observed at week 6 and  continued during the follow-up Figure 2
Significant reduction of CMT was observed at week 6 and 
continued during the follow-up.
Significant visual improvement occurred after 12 weeks and  persisted during the follow-up period Figure 1
Significant visual improvement occurred after 12 weeks and 
persisted during the follow-up period.BMC Ophthalmology 2007, 7:10 http://www.biomedcentral.com/1471-2415/7/10
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weeks. Retreatment was required in 63.6% of cases at
week 24 due to recurrent fluorescein leakage. Retreat-
ments consisted of repeat PDT and intravitreal bevacizu-
mab in these two case series.
The optimal time for intravitreal injection of bevacizumab
with or without a steroid after PDT is not known. It has
ranged from 16 hours[23] to 2 weeks [21] in published
series. We decided to inject bevacizumab and triamci-
nolone 48 hours after PDT to reduce the risk of light tox-
icity and to counteract the adverse effects of PDT induced
release of VEGF. The results of our study with this treat-
ment strategy are encouraging however, limitations
including the small number of patients and the absence of
control groups make it difficult to generalize the results.
Conclusion
Our preliminary results suggest that intravitreal bevacizu-
mab has a synergistic effect with PDT and intravitreal tri-
amcinolone for treatment of neovascular AMD. Using this
triple therapy as an initial pulse can improve or stabilize
visual acuity. In case of recurrent CNV, repeat intravitreal
injection of bevacizumab may help maintain the visual
gain. Further studies are required to confirm the results of
this pilot study.
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